CASI PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year Two
CASI PHARMACEUTICALS, INC. had Finite-Lived Intangible Asset, Expected Amortization, Year Two of $5.00 thousand as of 2022-12-31, per its 20-F filed 2023-04-26.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo · last filed 2023-04-26
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Two $5.00K.
- 2021-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Two $1.35M.
- 2021-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year Two $1.33M.
- 2021-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year Two $1.33M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Two |
|---|---|
| 2022-12-31 | $5.00K 20-F · filed 2023-04-26 |
| 2021-12-31 | $1.35M 10-K · filed 2022-03-28 |
| 2021-09-30 | $1.33M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $1.33M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.32M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.32M 10-K · filed 2021-03-30 |
| 2020-09-30 | $1.27M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $1.25M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.52M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.54M 10-K · filed 2020-03-16 |
| 2019-09-30 | $1.53M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.58M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.54M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $1.55M 10-K · filed 2019-03-29 |
| 2018-09-30 | $1.39M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $1.39M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $1.39M 10-Q · filed 2018-05-15 |